Welcome to our dedicated page for APIMEDS PHARMACEUTICALS US SEC filings (Ticker: APUS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on APIMEDS PHARMACEUTICALS US's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into APIMEDS PHARMACEUTICALS US's regulatory disclosures and financial reporting.
Apimeds Pharmaceuticals US, Inc. (APUS) filed an amended Form 4 to correct how an insider’s holdings are reported. The filing shows that 4,316,618 shares of common stock are held indirectly through Apimeds Inc. (“Apimeds Korea”), a wholly owned subsidiary of the reporting person.
The amendment explains that earlier filings incorrectly showed a Convertible Promissory Note of $184,833 and the related common shares as indirectly owned through Apimeds Korea. As of May 12, 2025, the reporting person had direct beneficial ownership of 2,099,747 common shares and indirect beneficial ownership of 4,316,618 common shares held by Apimeds Korea. The insider also disclaims beneficial ownership of the subsidiary-held shares for certain legal purposes.
Apimeds Pharmaceuticals US, Inc. updated the employment terms of its Chief Executive Officer, Erik Emerson. Effective November 13, 2025, the company increased the CEO’s annual base salary to $500,000. The amendment also enhances protection for the CEO if he is terminated by the company without cause, granting a severance payment equal to 24 months of base salary and benefits, along with immediate vesting of all unvested equity, subject to his signing a release of claims. If he is terminated for cause, or resigns without good reason, any unvested equity will be automatically forfeited without payment or additional consideration.
Apimeds Pharmaceuticals US, Inc. (APUS) — Form 4 insider activity: A director reported the grant of a stock option for 10,000 shares with an exercise price of $2.67 per share on 11/11/2025. The option expires on 11/11/2035 and was reported as directly owned.
The award vests in quarterly installments beginning October 1, 2025, becoming fully vested after three years. The option is not exercisable until stockholder approval is obtained to amend the company’s incentive plan to increase available shares. The award will vest in full upon a Change in Control as defined in the plan.
Apimeds Pharmaceuticals US, Inc. (APUS) reported a director’s stock option grant. On 11/11/2025, the reporting person received an option to buy 10,000 shares of common stock at an exercise price of $2.67 per share, expiring on 11/11/2035. The award was coded as an acquisition and priced at $0 for the derivative grant, with 10,000 derivative securities beneficially owned directly after the transaction.
The option vests in quarterly installments beginning October 1, 2025 over three years and becomes exercisable only after stockholder approval of an amendment to increase shares available under the incentive plan. It vests in full upon a Change in Control as defined in the plan.
Apimeds Pharmaceuticals US, Inc. (APUS) reported a Form 4 for a director showing a grant of a stock option for 10,000 shares at an exercise price of $2.67 on 11/11/2025.
The option expires on 11/11/2035 and vests quarterly beginning October 1, 2025, becoming fully vested after three years. It is not exercisable until stockholder approval of an amendment to the incentive plan to increase available shares. The option vests in full upon a Change in Control.
Apimeds Pharmaceuticals US, Inc. (APUS) reported a routine insider equity grant. A director received a stock option covering 10,000 shares on 11/11/2025 with an exercise price of $2.67 and an expiration date of 11/11/2035.
The option vests in quarterly installments beginning October 1, 2025, becoming fully vested after three years. It is not exercisable until stockholder approval is obtained for an amendment to the company’s incentive plan to increase shares available under the plan. The award vests in full upon a Change in Control as defined in the plan.
Apimeds Pharmaceuticals US, Inc. (APUS) disclosed a director stock option grant. On 11/11/2025, the reporting person acquired a stock option for 10,000 shares at an exercise price of $2.67, with an expiration date of 11/11/2035. The option was received for $0 and is held as Direct (D) ownership.
The award vests in quarterly installments beginning October 1, 2025 and will be fully vested after three years, subject to continued service on each vesting date. It is not exercisable until stockholder approval is obtained for an amendment to the Company’s incentive plan to increase available shares. The option will vest in full upon a Change in Control as defined in the plan.
Apimeds Pharmaceuticals US, Inc. (APUS) reported Q3 2025 results. The company recorded a net loss of $1,781,255 for the quarter and $4,845,845 for the nine months ended September 30, 2025. Operating expenses rose as the company ramped research and development and expanded general and administrative activity.
Cash was $6,986,617 as of September 30, 2025. The company completed an IPO on May 12, 2025, issuing 3,375,000 shares at $4.00 per share and generating net proceeds of $11.9 million. Management states available cash, together with IPO proceeds, is sufficient to fund the current operating plan for at least the next twelve months from the financial statement issuance date.
R&D expenses were $619,693 in Q3, driven mainly by clinical trial costs, while G&A totaled $1,224,546. Shares outstanding were 12,575,983 as of September 30, 2025. Subsequent to quarter-end, the company paid a non-refundable fee of $700,000 to waive certain underwriting rights and approved 510,500 stock options at an exercise price of $1.92. Disclosure controls and procedures were deemed not effective due to material weaknesses in internal control over financial reporting.
Apimeds Pharmaceuticals US, Inc. (APUS) director reported receiving a stock option grant. The option covers 3,000 shares of common stock at an exercise price of $1.92 per share, granted on 10/15/2025 and expiring on 10/15/2035.
The award vests in quarterly installments beginning October 1, 2025 and becomes fully vested after three years, subject to continued service. It is not exercisable until stockholder approval is obtained to amend the incentive plan to increase available shares. The option vests in full upon a Change in Control as defined in the plan.
Following the transaction, the reporting person beneficially owns 3,000 derivative securities on a direct basis.
Apimeds Pharmaceuticals US, Inc. (APUS) reported a director stock option grant on a Form 4. The award covers 3,000 stock options at an exercise price of $1.92, granted on October 15, 2025, and expiring on October 15, 2035. Vesting occurs quarterly beginning October 1, 2025 and completes after three years, contingent on continued service. The option is not exercisable until stockholders approve an amendment to increase shares under the incentive plan; it vests in full upon a Change in Control.
FAQ
What is the current stock price of APIMEDS PHARMACEUTICALS US (APUS)?
What is the market cap of APIMEDS PHARMACEUTICALS US (APUS)?
